Pilot Study of Reduced Venetoclax Exposure (NCT07163793)

🧪 Interventions in This Study

• Azacitidine (DRUG)
• Decitabine (DRUG)
• Venetoclax (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• Zuckerberg Cancer Center — New Hyde Park, New York

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Acute Myeloid Leukemia in Remission

• Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant — Buffalo, New York
• AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission — Houston, Texas

Explore by condition: All Acute Myeloid Leukemia in Remission clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.